Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy

Vivek Kumar, Neha Chaudhary, Mohit Garg, Charalampos S Floudas, Parita Soni, Abhinav B Chandra, Vivek Kumar, Neha Chaudhary, Mohit Garg, Charalampos S Floudas, Parita Soni, Abhinav B Chandra

Abstract

The indications of immune checkpoint inhibitors (ICIs) are set to rise further with the approval of newer agent like atezolimumab for use in patients with advanced stage urothelial carcinoma. More frequent use of ICIs has improved our understanding of their unique side effects, which are known as immune-related adverse events (irAEs). The spectrum of irAEs has expanded beyond more common manifestations such as dermatological, gastrointestinal and endocrine effects to rarer presentations involving nervous, hematopoietic and urinary systems. There are new safety data accumulating on ICIs in patients with previously diagnosed autoimmune conditions. It is challenging for clinicians to continuously update their working knowledge to diagnose and manage these events successfully. If diagnosed timely, the majority of events are completely reversible, and temporary immunosuppression with glucocorticoids, infliximab or other agents is warranted only in the most severe grade illnesses. The same principles of management will possibly apply as newer anti- cytotoxic T lymphocytes-associated antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1/PD-L1) antibodies are introduced. The current focus of research is for prophylaxis and for biomarkers to predict the onset of these toxicities. In this review we summarize the irAEs of ICIs and emphasize their growing spectrum and their management algorithms, to update oncology practitioners.

Keywords: checkpoint blockade; immune related adverse events; ipilimumab; irAEs; nivolumab; pembrolizumab.

References

    1. Abdel-Rahman O., Fouad M. (2016). Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Ther. Adv. Respir. Dis. 10, 183–193. 10.1177/1753465816636557
    1. Abu Samra K., Valdes-Navarro M., Lee S., Swan R., Foster C. S., Anesi S. D., et al. (2016). A case of bilateral uveitis and papillitis in a patient treated with pembrolizumab. Eur. J. Ophthalmol. 26, e46–e48. 10.5301/ejo.5000724
    1. Ahmad S., Lewis M., Corrie P., Iddawela M. (2012). Ipilimumab-induced thrombocytopenia in a patient with metastatic melanoma. J. Oncol. Pharm. Pract. 18, 287–292. 10.1177/1078155211411001
    1. Akhtari M., Waller E. K., Jaye D. L., Lawson D. H., Ibrahim R., Papadopoulos N. E., et al. . (2009). Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 Antibody). J. Immunother. 32, 322–324. 10.1097/CJI.0b013e31819aa40b
    1. Albarel F., Gaudy C., Castinetti F., Morange I., Conte-Devolx B., Grob J. J., et al. . (2015). Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. Eur. J. Endocrinol. 172, 195–204. 10.1530/EJE-14-0845
    1. Armand P., Nagler A., Weller E. A., Devine S. M., Avigan D. E., Chen Y. B., et al. . (2013). Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J. Clin. Oncol. 31, 4199–4206. 10.1200/JCO.2012.48.3685
    1. Arriola E., Wheater M., Galea I., Cross N., Maishman T., Hamid D., et al. . (2016). Outcome and biomarker analysis from a multicenter phase 2 study of ipilimumab in combination with carboplatin and etoposide as first-line therapy for extensive-stage SCLC. J. Thor. Oncol. 11, 1511–1521. 10.1016/j.jtho.2016.05.028
    1. Attia P., Phan G. Q., Maker A., V, Robinson M. R., Quezado M. M., Yang J. C., et al. . (2005). Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 23, 6043–6053. 10.1200/JCO.2005.06.205
    1. Barjaktarevic I. Z., Qadir N., Suri A., Santamauro J. T., Stover D. (2013). Organizing pneumonia as a side effect of ipilimumab treatment of melanoma. Chest 143, 858–861. 10.1378/chest.12-1467
    1. Berger R., Rotem-Yehudar R., Slama G., Landes S., Kneller A., Leiba M., et al. . (2008). Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin. Cancer Res. 14, 3044–3051. 10.1158/1078-0432.CCR-07-4079
    1. Berman D., Parker S. M., Siegel J., Chasalow S. D., Weber J., Galbraith S., et al. . (2010). Blockade of cytotoxic T-lymphocyte antigen- 4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun. 10, 11.
    1. Berthod G., Lazor R., Letovanec I., Romano E., Noirez L., Mazza Stalder J., et al. . (2012). Pulmonary sarcoid-like granulomatosis induced by ipilimumab. J. Clin. Oncol. 30, e156–e159. 10.1200/JCO.2011.39.3298
    1. Bilen M. A., Subudhi S. K., Gao J., Tannir N. M., Tu S.-M., Sharma P. (2016). Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. J. Immunother Cancer 4, 36. 10.1186/s40425-016-0139-8
    1. Borghaei H., Paz-Ares K. L., Horn L., Spigel D. R., Steins M., Ready N. E., et al. . (2015). Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N. Engl. J. Med. 373, 1627–1639. 10.1056/NEJMoa1507643
    1. Brahmer J., Reckamp K. L., Baas P., Crin,ò L., Eberhardt W. E., Poddubskaya E., et al. . (2015). Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373, 123–135. 10.1056/NEJMoa1504627
    1. Calabro L., Morra A., Fonsatti E., Cutaia O., Fazio C., Annesi D., et al. . (2015). Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. Lancet Respir Med. 3, 301–309. 10.1016/S2213-2600(15)00092-2
    1. Callahan M. K., Yang A., Tandon S., Xu Y., Subudhi S. K., Roman R. A., et al. (2011). Evaluation of serum IL-17 levels during ipilimumab therapy: correlation with colitis. J. Clin. Oncol. 29s:2505.
    1. Cappelli L. C., Gutierrez A. K., Baer A. N., Albayda J., Manno R. L., Haque U., et al. . (2017). Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann. Rheum. Dis. 76, 43–50. 10.1136/annrheumdis-2016-209595
    1. Corsello S. M., Barnabei A., Marchetti P., De Vecchis L., Salvatori R., Torino F. (2013). Endocrine side effects induced by immune checkpoint inhibitors. J. Clin. Endocrinol. Metab. 98, 1361–1375. 10.1210/jc.2012-4075
    1. Cortazar F. B., Marrone K. A., Troxell M. L., Ralto K. M., Hoenig M. P., Brahmer J. R., et al. . (2016). Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 90, 638–647. 10.1016/j.kint.2016.04.008
    1. Cousin S., Italiano A. (2016). Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities. Clin. Cancer Res. 22, 4550–4555. 10.1158/1078-0432.CCR-15-2569
    1. Delyon J., Mateus C., Lambert T. (2011). Hemophilia A induced by ipilimumab. N. Engl. J. Med. 365, 1747–1748. 10.1056/NEJMc1110923
    1. de Maleissye M.-F., Nicolas G., Saiag P. (2016). Pembrolizumab-Induced Demyelinating Polyradiculoneuropathy. N. Engl. J. Med. 375, 296–297. 10.1056/NEJMc1515584
    1. Du-Thanh A., Pallure V., Girard C., Dereure O., Guillot B. (2015). Clostridium difficile infection may loom behind ipilimumab-induced auto-immune colitis. Eur. J. Dermatol. 25, 344. 10.1684/ejd.2015.2561
    1. Eggermont A. M., Chiarion-Sileni V., Grob J. J., Dummer R., Wolchok J. D., Schmidt H., et al. . (2016). Prolonged survival in stage III Melanoma with Ipilimumab adjuvant therapy. N. Engl. J. Med. 375, 1845–1855. 10.1056/NEJMoa1611299
    1. Eggermont A. M., Chiarion-Sileni V., Grob J.-J., Dummer R., Wolchok J. D., Schmidt H., et al. (2015). Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 16, 522–530. 10.1016/S1470-2045(15)70122-1
    1. Fehrenbacher L., Spira A., Ballinger M., Kowanetz M., Vansteenkiste J., Mazieres J., et al. . (2016). Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016, 387, 1837–1846. 10.1016/S0140-6736(16)00587
    1. Ferris R. L., Blumenschein G., Jr., Fayette J., Guigay J., Colevas A. D., Licitra L., et al. . (2016). Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 375, 1856–1867. 10.1056/NEJMoa1602252
    1. Gangadhar T. C., Vonderheide R. H. (2014). Mitigating the toxic effects of anticancer immunotherapy. Nat. Rev. Clin. Oncol. 11, 91–99. 10.1038/nrclinonc.2013.245
    1. Garon E. B., Rizvi N. A., Hui R., Leighl N., Balmanoukian A. S., Eder J. P., et al. . (2015). Pembrolizumab for the treatment of non–small-cell lung cancer. N. Engl. J. Med. 372, 2018–2028. 10.1056/NEJMoa1501824
    1. Hamid O., Robert C., Daud A., Hodi F. S., Hwu W. J., Kefford R., et al. . (2013). Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369, 134–144. 10.1056/NEJMoa1305133
    1. Herbst R. S., Baas P., Kim D., Felip E., Pérez-Gracia J. L., Han J. Y., et al. . (2016). Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387, 1540–1550. 10.1016/S0140-6736(15)01281-7
    1. Hodi F., Lee S., McDermott D. F., Rao U. N., Butterfield L. H., Tarhini A. A., et al. . (2014). Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA 312, 1744–1753. 10.1001/jama.2014.13943
    1. Hodi F. S., O'Day S. J., McDermott D. F., Weber R. W., Sosman J. A., Haanen J. B., et al. . (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723. 10.1056/NEJMoa1003466
    1. Horvat T. Z., Adel N. G., Dang T. O., Momtaz P., Postow M. A., Callahan M. K., et al. . (2015). Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center. J. Clin. Oncol. 33, 3193. 10.1200/jco.2015.60.8448
    1. Huillard O., Bakalian S., Levy C., Desjardins L., Lumbroso-Le Rouic L., Pop S., et al. . (2014). Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic review. Eur. Cancer J. 50, 638–648. 10.1016/j.ejca.2013.10.016
    1. Ibrahim R., Berman D., de Pril V., V, Humphrey R. W., Chen T., Messina M., et al. (2011). Ipilimumab safety profile: summary of findings from completed trials in advanced melanoma. J. Clin. Oncol. 29 (abstract).
    1. Izzedine H., Gueutin V., Gharbi C., Mateus C., Robert C., Routier E., et al. . (2014). Kidney injuries related to ipilimumab. Invest. New Drugs 32, 769. 10.1007/s10637-014-0092-7
    1. Jaber S. H., Cowen E. W., Haworth L. R., Booher S. L., Berman D. M., Rosenberg S. A., et al. . (2006). Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent. Arch. Dermatol. 142, 166–172. 10.1001/archderm.142.2.166
    1. Johncilla M., Misdraji J., Pratt D. S., Agoston A. T., Lauwers G. Y., Srivastava A., et al. (2015). Ipilimumab-associated Hepatitis: Clinico pathologic Characterization in a Series of 11 Cases. Am. J. Surg. Pathol. 39, 1075–1084. 10.1097/PAS.0000000000000453
    1. Johnson D. B., Sullivan R. J., Ott P. A., Carlino M. S., Khushalani N., I, Ye F., et al. . (2015). Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune. JAMA Oncol. 2, 234–240. 10.1001/jamaoncol.2015.4368
    1. Kindler H. L., Scherpereel A., Calabrò L., Aerts J., Perez S. C., Bearz A., et al. (2016). Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): Results from the global, double-blind, placebo-controlled DETERMINE study. J. Clin. Oncol. 34 (abstract).
    1. Kong B. Y., Micklethwaite K. P., Swaminathan S., Kefford R. F., Carlino M. S. (2016). Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma. Melanoma Res. 26, 202–204. 10.1097/CMR.0000000000000232
    1. Langer C. J. (2015). Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors. Am. J. Clin. Oncol. 38, 422–430. 10.1097/coc.0000000000000059
    1. Larkin J., Chiarion-Sileni V., Gonzalez R., Grob J. J., Cowey C. L., Lao C. D., et al. (2015). Combined nivolumab and ipilimumab or Monotherapy in Untreated Melanoma. N. Engl. J. Med. 373, 23–34. 10.1056/NEJMoa1504030
    1. Liao B., Shroff S., Kamiya-Matsuoka C., Tummala S. (2014). Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro-oncology 16, 589–593. 10.1093/neuonc/nou001
    1. Massard C., Gordon M. S., Sharma S., Rafii S., Wainberg Z. A., Luke J., et al. . (2016). Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J. Clin. Oncol. 34, 3119–3125. 10.1200/JCO.2016.67.9761
    1. Maur M., Tomasello C., Frassoldati A., Dieci M., V, Barbieri E., Conte P., et al. . (2012). Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. J. Clin. Oncol. 30, e76–e78. 10.1200/JCO.2011.38.7886
    1. Min L., Hodi F. S., Giobbie-Hurder A., Ott P. A., Luke J. J., Donahue H., et al. (2015). Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. Clin. Cancer Res. 21, 749–755. 10.1158/1078-0432.CCR-14-2353
    1. Minor D., Chin K., Kashani-Sabet M. (2009). Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis. Cancer Biother. Radiopharm. 24, 321–325. 10.1089/cbr.2008.0607
    1. Momtaz P., Park V., Panageas K. S., Postow M. A., Callahan M., Wolchok J. D., et al. (2015). Safety of Infusing ipilimumab Over 30 Minutes. J. Clin. Oncol. 33, 3454–3458. 10.1200/JCO.2015.61.0030
    1. Naidoo J., Page D. B., Li B. T., Connell L. C., Schindler K., Lacouture M. E., et al. (2015). Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann. Oncol. 26, 2375 10.1093/annonc/mdv383
    1. Nanda R., Chow L. Q., Dees E. C., Berger R., Gupta S., Geva R., et al. (2016). Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J. Clin. Oncol. 34, 2460–2467. 10.1200/JCO.2015.64.8931
    1. National Cancer Institute (2009). Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Available online at:
    1. Oble D. A., Mino-Kenudson M., Goldsmith J., Hodi F. S., Seliem R. M., Dranoff G., et al. (2008). Alpha-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysis. Am. J. Surg. Pathol. 32, 1130–1137. 10.1097/PAS.0b013e31817150e3
    1. Postow M. A., Chesney J., Pavlick A. C., Robert C., Grossmann K., McDermott D., et al. (2015). Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372, 2006–2017. 10.1056/NEJMoa1414428
    1. Postow M., Wolchok J. (2016). Toxicities associated with checkpoint inhibitor immunotherapy, in UpToDate, ed Post T. W. (Waltham, MA: ). (Accessed: August 1, 2016).
    1. Reck M., Rodríguez-Abreu D., Robinson A. G., Hui R., Cőszi T., Fülöp A., et al. (2016). Pembrolizumab versus Chemotherapy for PD-L1–Positive non–small-cell lung cancer. N. Engl. J. Med. 375, 1823–1833. 10.1056/NEJMoa1606774
    1. Ribas A., Hodi F. S., Callahan M., Konto C., Wolchok J. (2013a). Hepatotoxicity with combination of vemurafenib and ipilimumab. N. Engl. J. Med. 368, 1365–1366. 10.1056/nejmc1302338
    1. Ribas A., Kefford R., Marshall M. A., Punt C. J., Haanen J. B., Marmol M., et al. (2013b). Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J. Clin. Oncol. 31, 616–622. 10.1200/JCO.2012.44.6112
    1. Rittmeyer A., Barlesi F., Waterkamp D., Park K., Ciardiello F., von Pawel J., et al. (2017). Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389, 255–265. 10.1016/S0140-6736(16)32517-X
    1. Rizvi N. A., Mazières J., Planchard D., Stinchcombe T. E., Dy G. K., Antonia S. J., et al. (2015). Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 16, 257–265. 10.1016/S1470-2045(15)70054-9
    1. Robert C., Long G., V, Brady B., Dutriaux C., Maio M., Mortier L., et al. (2015a). Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320–330. 10.1056/NEJMoa1412082
    1. Robert C., Schachter J., Long G., V, Arance A., Grob J. J., Mortier L., et al. (2015b). Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521–2532. 10.1056/NEJMoa1503093
    1. Robert C., Thomas L., Bondarenko I., O'Day S., Weber J., Garbe C., et al. (2011). Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517–2526. 10.1056/NEJMoa1104621
    1. Rosenberg J. E., Jean H., Tom P., van der Heijden M. S., Balar A., V, Necchi A., et al. (2016). Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387, 1909–1920. 10.1016/S0140-6736(16)00561-4
    1. Ryder M., Callahan M., Postow M., Wolchok J., Fagin J. A. (2014). Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr. Relat. Cancer 21, 371–381. 10.1530/ERC-13-0499
    1. Schindler K., Harmankaya K., Kuk D. (2014). Correlation of absolute and relative eosinophil counts with immune-related adverse events in melanoma patients treated with ipilimumab. J. Clin. Oncol. 32:5s (abstract).
    1. Seiwert T. Y., Burtness B., Mehra R., Weiss J., Berger R., Eder J. P., et al. (2016). Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 17, 956–965. 10.1016/S1470-2045(16)30066-3
    1. Shahabi V., Berman D., Chasalow S. D., Wang L., Tsuchihashi Z., Hu B., et al. (2013). Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune- related gastrointestinal adverse events. J. Transl. Med. 11:75 10.1186/1479-5876-11-75
    1. Tarhini A. A., Cherian J., Moschos S. J., Tawbi H. A., Shuai Y., Gooding W. E., et al. (2012). Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J. Clin. Oncol. 30, 322–328. 10.1200/JCO.2011.37.5394
    1. Topalian S. L., Hodi F. S., Brahmer J. R., Gettinger S. N., Smith D. C., McDermott D. F., et al. (2012). Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443 10.1056/NEJMoa1200690
    1. Topalian S. L., Sznol M., McDermott D., Kluger F. H. M., Carvajal R. D., Sharfman W. H., et al. (2014). Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 32, 1020–1030. 10.1200/JCO.2013.53.0105
    1. Villadolid J., Amin A. (2015). Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl. Lung Cancer Res. 4, 560–575. 10.3978/j.issn.2218-6751.2015.06.06
    1. Weber J. (2009). Ipilimumab: Controversies in its development, utility, and autoimmune adverse events. Cancer Immunol. Immunother. 58, 823–830. 10.1007/s00262-008-0653-8
    1. Weber J., Hamid O., Amin A., Masson E., Goldberg S. M., Williams D., et al. (2013). Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. Cancer Immun. 13, 7.
    1. Weber J. S. (2012). Practical Management of immune related adverse events from immune checkpoint protein antibodies for the oncologist. Am. Soc. Clin. Oncol. Educ. Book 2012, 174–177. 10.14694/EdBook_AM.2012.32.174
    1. Weber J. S., Kudchadkar R. R., Yu B. (2013). Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J. Clin. Oncol. 31, 4311 10.1200/jco.2013.51.4802
    1. Weber J. S., Yang J. C., Atkins M. B., Disis M. L. (2015). Toxicities of Immunotherapy for the Practitioner. J. Clin. Oncol. 10.1200/jco.2014.60.0379
    1. Weber J., Thompson J. A., Hamid O., Minor D., Amin A., Ron I., et al. (2009). A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin. Cancer Res. 15, 5591–5598. 10.1158/1078-0432.CCR-09-1024
    1. Westin J. R., Chu F., Zhang M., Fayad L. E., Kwak L. W., Fowler N., et al. (2014). Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 15, 69–77. 10.1016/S1470-2045(13)70551-5
    1. Wilgenhof S., Neyns B. (2011). Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient. Ann. Oncol. 22, 991–993. 10.1093/annonc/mdr028
    1. Williams T. J., Benavides D. R., Patrice K. A., Dalmau J. O., de Ávila A. L., Le D. T., et al. (2016). Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol. 73, 928–933. 10.1001/jamaneurol.2016.1399
    1. Wolchok J. D., Neyns B., Linette G., Negrier S., Lutzky J., Thomas L., et al. (2010). Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 11, 155–164. 10.1016/S1470-2045(09)70334-1

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner